Trial Spotlight

FORAGER-1; NCT05614739

A Phase 1, Open-label, Multicenter Study of LY3866288 (LOXO-435) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer with FGFR3 Alterationsa

Filter our pipeline to find information relevant to you. Search results will appear below.
Enrolling

Breast

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
CDK4/6 Inhibitor
3
Not enrolling
CDK4/6 Inhibitor
3
Not enrolling
CDK4/6 Inhibitor
3
Not enrolling
CDK4/6 Inhibitor
3
Not enrolling
FRα Antibody-Drug Conjugate
1
Enrolling
Nectin-4 Antibody-Drug Conjugate 1
1
Enrolling
Nectin-4 Antibody-Drug Conjugate 2
1
Enrolling
Next-Generation PI3Kα Inhibitor
PRECLINICAL
Selective Estrogen Receptor Degrader
1
Not enrolling
Selective Estrogen Receptor Degrader
3
Not enrolling
Selective Estrogen Receptor Degrader
3
Enrolling

Gastrointestinal

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
FRα Antibody-Drug Conjugate
1
Enrolling
KRAS G12C Inhibitor
2
Enrolling
KRAS G12D Inhibitor
1
Enrolling
Nectin-4 Antibody-Drug Conjugate 1
1
Enrolling
Nectin-4 Antibody-Drug Conjugate 2
1
Enrolling
Pan-KRAS Inhibitor
1
Enrolling

Genitourinary

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
FGFR3 Inhibitor
1
Enrolling
Nectin-4 Antibody-Drug Conjugate 1
1
Enrolling
Nectin-4 Antibody-Drug Conjugate 2
1
Enrolling
Prostate-Specific Membrane Antigen (PSMA) Radioligand
1
Enrolling

Gynecologic

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
FRα Antibody-Drug Conjugate
1
Enrolling
Nectin-4 Antibody-Drug Conjugate 1
1
Enrolling
Nectin-4 Antibody-Drug Conjugate 2
1
Enrolling
Selective Estrogen Receptor Degrader
1
Not enrolling

Hematologic

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
BAFF-R T-Cell Engager
PRECLINICAL
BTK Inhibitor
2
Not enrolling
BTK Inhibitor
3
Not enrolling
BTK Inhibitor
3
Not enrolling
BTK Inhibitor
3
Not enrolling
BTK Inhibitor
3
Not enrolling
BTK Inhibitor
3
Not enrolling

Lung

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
FRα Antibody-Drug Conjugate
1
Enrolling
KRAS G12C Inhibitor
2
Enrolling
KRAS G12C Inhibitor
3
Enrolling
KRAS G12D Inhibitor
1
Enrolling
Nectin-4 Antibody-Drug Conjugate 1
1
Enrolling
Nectin-4 Antibody-Drug Conjugate 2
1
Enrolling
Pan-KRAS Inhibitor
1
Enrolling
PTK7 Antibody-Drug Conjugate
PRECLINICAL
RET Inhibitor
3
Not enrolling
RET Inhibitor
3
Enrolling
SMARCA2 (BRM) Inhibitor
1
Enrolling
VEGF Receptor-2 Antagonist
3
Not enrolling

Other Solid Tumors

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
CDK4/6 Inhibitor
2
Not enrolling
CDK4/6 Inhibitor
2
Enrolling
FGFR3 Inhibitor
1
Enrolling
KRAS G12C Inhibitor
2
Enrolling
KRAS G12D Inhibitor
1
Enrolling
Nectin-4 Antibody-Drug Conjugate 1
1
Enrolling
Nectin-4 Antibody-Drug Conjugate 2
1
Enrolling
Next-Generation PI3Kα Inhibitor
PRECLINICAL
Pan-KRAS Inhibitor
1
Enrolling
PTK7 Antibody-Drug Conjugate
PRECLINICAL
RET Inhibitor
2
Not enrolling
RET Inhibitor
2
Not enrolling
SMARCA2 (BRM) Inhibitor
1
Enrolling

Sarcoma

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
CDK4/6 Inhibitor
2
Not enrolling
VEGF Receptor-2 Antagonist
2
Not enrolling

Thyroid

Mechanism of Action
Molecule
Trial Identifier
Phase
Status
RET Inhibitor
2
Not enrolling
RET Inhibitor
3
Not enrolling